Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 478 participants.

Also called NCT05950516

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 478 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05950516
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05950516. Randomized; no masking; primary purpose treatment. Start 2023-07-10 (anticipated); primary completion 2024-11-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
Intervention (Drug)
Semaglutide
Intervention (Drug)
Semaglutide Pen Injector [Ozempic]
Lead sponsor
Qilu Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05950516
Content hash
db6869a134e79b72e85c4948c9cef2ec791518ddb55458f4107de0787fdfc3a7